不同剂量舒利迭对不同表型重度稳定期COPD的临床疗效研究(1)
 |
| 第1页 |
参见附件(2741KB，3页)。
[摘要] 目的 观察舒利迭(沙美特罗/氟替卡松吸入剂)不同剂量对重度(GOLD Ⅲ级)稳定期慢性阻塞性肺疾病(COPD)不同表型(普通型与伴气道高反应型)的临床疗效。方法 选取120例稳定期重度COPD患者，其中伴气道高反应性者60例，随机分成两组，各30例，普通型者60例，也均分成两组，各30例，设立一个对照组给予口服茶碱缓释片(0.1mg一日两次口服)及酮替酚片(1mg一日两次口服)，三个观察组，给予吸入不同剂量的舒利迭，疗程均为3个月。治疗前后测定1秒量占预计值百分比(FEV1%)及用力肺活量占预计值的百分比(FEV1%)、1秒率(FEV1/FVC)。结果 102例患者最终完成试验，对照组治疗前后肺功能FVC%、FEV1%、FEV1/FVC有所改善，但无统计学意义(P>0.05)，三观察组肺功能改善均较对照组明显改善(P<0.05)，且实验组间伴气道高反应性者改善明显。 结论 沙美特罗/氟替卡松吸入剂治疗COPD疗效肯定，对伴气道高反应性者疗效更好。
[关键词] 舒利迭；慢性阻塞性肺疾病；气道高反应性；表型
[中图分类号] R563.9 [文献标识码] B [文章编号] 1673-9701(2011)36-158-03
Clinical Observation of the Efficacy of Inhaling Salmeterol and Different Doses of Fluticasone Powder for the Treatment of Severe Stable COPD with Different Phenotype
CHEN Kai ZHAI Xiumei ZHENG Li
People's Hospital of Yongcheng City in Henan Province，Yongcheng 476600, China.
[Abstract] Objective To observe on SERETIDE (SALMETEROL/FLUTICASONE INHALATION) at different doses on severe (GOLD grade) the stable phase of chronic obstructive pulmonary disease (COPD) with different phenotypes (common type with high reaction of airway type) clinical efficacy. Methods All of 120 patients with severe stable COPD, in which 60 cases has airway hyperresponsiveness, were randomly divided into 2 groups(30 cases each); the remaining 60 cases were ordinary type, they were divided into 2 more groups(30 cases each). From the above 4 groups, a control group was set up by given ORAL THEOPHYLLINE SUSTAINED-RELEASED tablets(0.1g two times a day orally) and KETOTIFEN FUMARATE tablets (1mg two times a day orally). The remaining 3 groups were set up as observation group by given different doses of SERETIDE INHALATION. The treatment course casted for 3 months. A second volume determined before and after treatment(FEV1%) and FVC% predicted the percentage value (FEV1%), a second rate (FEV1/FVC). Results All of 102 patients completed the final test. The control group of lung function before and after therapy, FEV1%, FEV1 FVC%/FVC had improved but there was no statistical significance(P>0 ......
您现在查看是摘要介绍页，详见PDF附件(2741KB，3页)。